<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574089</url>
  </required_header>
  <id_info>
    <org_study_id>PUShenzhenH</org_study_id>
    <nct_id>NCT04574089</nct_id>
  </id_info>
  <brief_title>Treatment for Aerobic Vaginitis by Using Bofukang Vaginal Suppository</brief_title>
  <official_title>Medical Ethics Committee of Peking University Shenzhen Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang&#xD;
      Suppository 14 days group.To evaluate the efficacy and safety after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aerobic vaginitis was treated by using Baofukang Suppository 7 days group or Baofukang&#xD;
      Suppository 14 days group.&#xD;
&#xD;
      Group 1: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 7 days.&#xD;
&#xD;
      Group 2: Baofukang Suppository (1.74g), for vaginal use, 2 capsules per night for 14 days.&#xD;
&#xD;
      The efficacy and safety will be evaluated 7~14 days after treatment and 35~42 days after&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate</measure>
    <time_frame>First week after treatment</time_frame>
    <description>A vaginal smear composite Donders score of 1 to 2 represents normality. A score of more than 2 is aerobic vaginitis. There are four variables(Lactobacillary; leucocytes; toxic leukocytes; parabasal cells; background flora). Detail see references Links.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cure rate</measure>
    <time_frame>First month after the treatment</time_frame>
    <description>A vaginal smear composite Donders score of 1 to 2 represents normality. A score of more than 2 is aerobic vaginitis. There are four variables(Lactobacillary; leucocytes; toxic leukocytes; parabasal cells; background flora).Detail see folowing references.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side affect</measure>
    <time_frame>First week after treatment</time_frame>
    <description>Number of Participants Experiencing AEs Following the First Dose of the Study Product</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Vaginitis</condition>
  <arm_group>
    <arm_group_label>Baofukang Suppository 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baofukang Suppository 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baofukang Suppository (1.74g), for vaginal external use, 2 capsules per night for 14days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Baofukang Suppository 7 days</intervention_name>
    <description>Experimental: Baofukang Suppository 7 days</description>
    <arm_group_label>Baofukang Suppository 7 days</arm_group_label>
    <other_name>Baofukang Suppository 7 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental: Baofukang Suppository 14 days</intervention_name>
    <description>Experimental: Baofukang Suppository 14 days</description>
    <arm_group_label>Baofukang Suppository 14 days</arm_group_label>
    <other_name>Baofukang Suppository 14 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Aerobic vaginitis diagnosed based on present ：&#xD;
&#xD;
          1. Vaginal dischareg ;&#xD;
&#xD;
          2. pH &gt; 4.5;&#xD;
&#xD;
          3. Donders score≥3;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with other vaginitis, cervical erosion, or suspected gonorrhea, herpes&#xD;
             simplex virus infection and other vulvar diseases;&#xD;
&#xD;
          2. Patients received systemic or vaginal antifungal or antibiotic treatment within two&#xD;
             weeks before admission.&#xD;
&#xD;
          3. Pregnancy, lactation and intentional pregnancy;&#xD;
&#xD;
          4. Women with liver and kidney dysfunction, low immune function, diabetes, psychosis or&#xD;
             other serious diseases;&#xD;
&#xD;
          5. Allergic constitution and patients allergic to drug ingredients in this study;&#xD;
&#xD;
          6. Those with poor compliance.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with sexual activity</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shangrong Fan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Liu, M.D.</last_name>
    <phone>86755-83923333</phone>
    <phone_ext>5505</phone_ext>
    <email>253783006@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiheng Liang, M.D.</last_name>
    <phone>86755-83923333</phone>
    <phone_ext>5518</phone_ext>
    <email>13510331823@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Shenzhen Hosptal</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://obgyn.onlinelibrary.wiley.com/doi/full/10.1111/j.1471-0528.2002.00432.x?sid=nlm%3Apubmed</url>
    <description>AV diagnosis and outcome Measure</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Aerobic vaginitis</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

